June 8, 2009 (FinancialWire) — Ingen Technologies, Inc. (OTC: IGNT), a leading Medical device manufacturer, announced that the company has accepted the termination from Thermotex regarding the acquisition.

Francis Docherty, president of the Canadian-based Thermotex Therapy Systems, LTD, had signed a letter of intent on March 12, 2009 agreeing to forward financial and intellectual property documents. To date, Ingen had not received any of the requested documents from Thermotex.

“I’ve been in discussions with Docherty during the past two months, and have expressed on several occasions our concern that he has not complied with the deliverable of the due diligence documents agreed to in the letter of intent. The termination of this acquisition is warranted since Thermotex is unwilling to comply with the terms specified. Our focus is on our new Oxyview-Cannula, and the marketing and sale of this product in June. It would not be in the best interest of our shareholders to waste any further time with Thermotex,” stated Scott R. Sand, chief executive officer and chairman of the board.

Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the U.S., and $8 billion globally.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.